Key facts
- This page summarizes William C. Bertrand Jr.'s Form 4 filing for Adaptimmune Therapeutics PLC (ADAP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 29 Aug 2025, 18:25.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Additional SEC filing notes
Footnote F1
The ordinary shares whose sale is reported on this line are represented by American Depositary Shares ("ADS") and are held in the form of ADSs by the Reporting Person. Each ADS represents six ordinary shares of the Issuer.
Footnote F2
The 207,000 ordinary shares reported in Column 4 are represented by 34,500 ADSs.
Footnote F3
The price reported in Column 4 of $0.01005 per ordinary share is derived from the sale price of $0.0603 per ADS divided by six. These ADSs were sold in multiple transactions at a price of $0.0603. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission with full information regarding the ADSs sold at this price in this footnote.
Footnote F4
The 986,352 ordinary shares reported in Column 5 are held in the form of 164,392 ADSs by the Reporting Person and represent solely those ADSs held by the Reporting Person following this transaction. Additionally, the Reporting Person holds RSU-style options and other options covering an aggregate of 16,108,722 ordinary shares of the Issuer.